Jasper Therapeutics' Briquilimab Asthma Trial Approved by Health Canada, Begins Q4 2024
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics has received approval from Health Canada for a Phase 1b/2a clinical trial of briquilimab, targeting asthma. The trial will begin in Q4 2024, with initial data expected in the second half of 2025.
September 10, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jasper Therapeutics has received Health Canada approval for a Phase 1b/2a trial of briquilimab for asthma, set to start in Q4 2024. This marks a significant step in their clinical development pipeline.
The approval of the clinical trial by Health Canada is a positive regulatory milestone for Jasper Therapeutics, potentially increasing investor confidence and interest in the company's future prospects. The trial's success could lead to further development and commercialization opportunities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100